摘要
Dear Editor Hepatocellular carcinoma(HCC)is among the most com-mon cancers worldwide,causing about 600,000 deaths annully[1].In HCC,stem cell-like characteristics,which drive early recurrence and therapy resistance,are major contributors to poor prognosis[2].In this current study,we integrated and analyzed gene expression data from human fetal liver cells and primary HCC tumors(n=1231)and.uncovered two clinically and biologically distinct hepatic stem cell(HS)subtypes,potential biomarkers associated with these subtypes,and a potential new therapeutic inter-vention for these subtypes.
基金
supported in part by National Cancer Institute grants R01-CA237327 and P50-CA217674,the Duncan Cancer Prevention Research Seed Funding Pro-gram at MD Anderson Cancer Center(2016 cycle),the MD Anderson Sister Institution Network Fund(2016 and 2019 cycles),and the National Institutes of Health through MD Anderson’s Cancer Center Support Grant,P30-CA016672.Acquisition of blood samples was sup-ported by grants R01-CA165076,P30-CA015083(Survey Research Shared Resource at Mayo Clinic Cancer Center),and P50-CA210964(Mayo Clinic Hepatobiliary SPORE,to L.R.R.).S.H.L.was supported by the Severance Research Initiative(SRI)project in Yonsei University College of Medicine.
